Peptide regulation in 2026: the tracker
Every FDA, HHS and anti-doping change that affects peptides and other injectables covered on Drawline, newest first, with what it does and does not mean and a source for each.
Updated · Sourced to FDA, HHS, the Federal Register and anti-doping agencies
The short version
- No peptide covered here became FDA-approved in 2026 except orforglipron (Foundayo), a GLP-1 pill.
- The July 2026 advisory votes and the October 2026 HHS draft concern pharmacy compounding, not approval. They change nothing legally until FDA finishes rulemaking, and the HHS draft can be withdrawn.
- Products sold as "research use only" are still not for human use.
Timeline
| Date | What happened | Compounds | Source |
|---|---|---|---|
| October 30, 2026 | HHS published a draft policy saying it does not intend to take action against pharmacies and physicians that compound certain peptides under set conditions while FDA decides through rulemaking. It is a decision not to enforce, not approval, and it can be withdrawn. | BPC-157, TB-500, MOTS-c, Semax | HHS: enforcement discretion policy for compounding certain peptides (draft) Federal Register: HHS draft peptide compounding policy, October 30, 2026 |
| August 27, 2026 | FDA told compounders not to use dietary-supplement-grade glutathione in injectables, after at least 30 people had reactions such as fever, chills and shock-like illness. | Glutathione | FDA: do not use dietary supplement grade glutathione for injectables, August 2026 |
| July 23 and 24, 2026 | An FDA advisory committee voted on adding peptides to the list of substances pharmacies may compound. It narrowly recommended BPC-157 (for ulcerative colitis) and TB-500 (for wound healing), recommended MOTS-c 7 to 5 (for obesity and osteoporosis) and Semax (against the advice of FDA staff), and voted against DSIP. KPV was also on the agenda. The votes are advisory: nothing changes legally until FDA finishes rulemaking. | BPC-157, TB-500, MOTS-c, Semax, DSIP | FDA: Pharmacy Compounding Advisory Committee, July 23 and 24, 2026 AJMC: FDA panel backs 6 peptides for compounding |
| 2026 | FDA moved several withdrawn nominations, including Semax, Selank, DSIP and thymosin alpha 1, to a table of withdrawn nominations while keeping its safety notes. Leaving the safety-risk list does not make a substance approved or eligible for compounding. | Semax, Selank, DSIP, Thymosin alpha 1 | FDA: bulk drug substances that may present significant safety risks |
| April 1, 2026 | FDA approved orforglipron as Foundayo for weight management, a GLP-1 taken as a pill. | Orforglipron | Managed Healthcare Executive: GLP-1 pills |
| December 2024 | An FDA advisory committee voted against adding thymosin alpha 1 to the list of substances pharmacies may compound. | Thymosin alpha 1 | FDA: advisory committee minutes, December 2024 |
| October 2024 | FDA warned that some pharmacies were making IV NAD+ from food-grade ingredients that are not suitable for sterile products, and reported reactions consistent with bacterial toxins. | NAD+ | FDA: use ingredients suitable for sterile compounding (NAD+), October 2024 |
| June 28, 2023 | FDA withdrew approval of Oxandrin (oxandrolone) and its generics, and later found it had been withdrawn for reasons of safety or effectiveness. | Oxandrolone | Federal Register: withdrawal of approval of Oxandrin |
| 2023 | FDA listed several peptides, including BPC-157, CJC-1295, ipamorelin and injectable GHK-Cu, among bulk substances that may present significant safety risks in compounding. | BPC-157, CJC-1295 and ipamorelin, GHK-Cu | FDA: bulk drug substances that may present significant safety risks |
What to watch next
- Late 2026: FDA decision expected on orforglipron for type 2 diabetes. (Orforglipron)
- January 1, 2027: The 2027 World Anti-Doping Code Prohibited List names unapproved peptides. Athletes should check with their anti-doping agency.
- By February 2027: FDA advisory committee review expected for GHK-Cu and Melanotan II. (GHK-Cu, Melanotan II)
- First quarter of 2027: The manufacturer of retatrutide plans to file for FDA approval. (Retatrutide)
- Open: FDA rulemaking on the compounding list, and a final version of the HHS policy. Until then, the July 2026 votes and the October 2026 draft change nothing legally.
What the terms mean
FDA approval means FDA reviewed evidence that a specific product is safe and effective for a specific use. Nothing short of that is approval.
The compounding list (the 503A bulks list) names substances pharmacies may use to compound a prescribed drug. An advisory committee vote is a recommendation to FDA, which then decides through rulemaking.
Enforcement discretion means an agency says it will not act against certain conduct for now. It does not make the conduct legal or approved, and it can end at any time.
Safety-risk list (often called Category 2): substances FDA said may present significant safety risks in compounding.
For how these statuses differ in practice, read approved, compounded or research-only. Each compound's current position is on its profile.
Questions
Did FDA approve BPC-157 in 2026?
No. In July 2026 an FDA advisory committee narrowly recommended adding BPC-157 to the list of substances pharmacies may compound. That is advisory, not approval, and nothing changes legally until FDA finishes rulemaking.
What did HHS announce about peptides in October 2026?
A draft policy saying HHS does not intend to take action against pharmacies and physicians that compound certain peptides, including BPC-157, TB-500, MOTS-c and Semax, under set conditions while FDA decides through rulemaking. It is not approval and can be withdrawn.
Which peptides did the July 2026 FDA committee vote on?
It recommended BPC-157, TB-500, MOTS-c and Semax for the compounding list and voted against DSIP. KPV was also on the agenda. The votes are advisory.
Sources: HHS: enforcement discretion policy for compounding certain peptides (draft); Federal Register: HHS draft peptide compounding policy, October 30, 2026; FDA: do not use dietary supplement grade glutathione for injectables, August 2026; FDA: Pharmacy Compounding Advisory Committee, July 23 and 24, 2026; AJMC: FDA panel backs 6 peptides for compounding; FDA: bulk drug substances that may present significant safety risks; Managed Healthcare Executive: GLP-1 pills; FDA: advisory committee minutes, December 2024; FDA: use ingredients suitable for sterile compounding (NAD+), October 2024; Federal Register: withdrawal of approval of Oxandrin; USADA: athlete advisory on the 2027 Prohibited List.
For research and educational use. Not medical advice or legal advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.
Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.